Michael Dews1, Grace S Tan, Stacy Hultine, Pichai Raman, Jaewoo Choi, Elizabeth K Duperret, Jack Lawler, Adam Bass, Andrei Thomas-Tikhonenko. 1. Affiliations of authors: Division of Cancer Pathobiology, Center for Childhood Cancer Research (MD, GST, SH, AT-T) and Center for Biomedical Informatics (PR), Children's Hospital of Philadelphia, Philadelphia, PA; Cancer Biology Graduate Program (JC, EKD, AT-T) and Department of Pathology & Laboratory Medicine (AT-T), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Experimental Pathology, Beth Israel Deaconess Medical Center (JL) and Department of Medical Oncology, Dana-Farber Cancer Institute (AB), Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: The c-Myc oncoprotein is activated in the majority of colorectal cancers (CRCs), whereas the TGF-β pathway is frequently affected by loss-of-function mutations, for example in SMAD2/3/4 genes. The canonical model places Myc downstream of inhibitory TGF-β signaling. However, we previously demonstrated that Myc also inhibits TGF-β signaling through the miR-17~92 microRNA cluster, raising the question about functional relationships between these two pathways. METHODS: We engineered a series of genetically complex murine and human CRC cell lines in which Myc and TGF-β activities could be manipulated simultaneously. This was achieved through retroviral expression of the Myc-estrogen receptor fusion protein and through Smad4 short hairpin RNA knockdown. Cell lines thus modified were injected subcutaneously in immunocompromised mice, and the resultant tumors (n = 5-10 per treatment group) were analyzed for overall growth and neovascularization. Additionally, the distribution of MYC and TGF-β pathway mutations was analyzed in previously profiled human CRC samples. RESULTS: In kras-mutated/trp53-deleted murine colonocytes, either Myc activation or TGF-β inactivation increased tumor sizes and microvascular densities approximately 1.5- to 2.5-fold, chiefly through downregulation of thrombospondin-1 and related type I repeat-containing proteins. Combining Myc activation with TGF-β inactivation did not further accelerate tumorigenesis. This redundancy and the negative effect of TGF-β signaling on angiogenesis were also demonstrated using xenografts of human CRC cell lines. Furthermore, the analysis of the Cancer Genome Atlas data revealed that in CRC without microsatellite instability, overexpression of Myc and inactivation of Smads (including acquired mutations in SMAD2) are mutually exclusive, with odds ratio less than 0.1. CONCLUSIONS: In human CRC, gain-of-function alterations in Myc and loss-of-function alterations in TGF-β exhibit a masking epistatic interaction and are functionally redundant.
BACKGROUND: The c-Myc oncoprotein is activated in the majority of colorectal cancers (CRCs), whereas the TGF-β pathway is frequently affected by loss-of-function mutations, for example in SMAD2/3/4 genes. The canonical model places Myc downstream of inhibitory TGF-β signaling. However, we previously demonstrated that Myc also inhibits TGF-β signaling through the miR-17~92 microRNA cluster, raising the question about functional relationships between these two pathways. METHODS: We engineered a series of genetically complex murine and human CRC cell lines in which Myc and TGF-β activities could be manipulated simultaneously. This was achieved through retroviral expression of the Myc-estrogen receptor fusion protein and through Smad4 short hairpin RNA knockdown. Cell lines thus modified were injected subcutaneously in immunocompromised mice, and the resultant tumors (n = 5-10 per treatment group) were analyzed for overall growth and neovascularization. Additionally, the distribution of MYC and TGF-β pathway mutations was analyzed in previously profiled human CRC samples. RESULTS: In kras-mutated/trp53-deleted murine colonocytes, either Myc activation or TGF-β inactivation increased tumor sizes and microvascular densities approximately 1.5- to 2.5-fold, chiefly through downregulation of thrombospondin-1 and related type I repeat-containing proteins. Combining Myc activation with TGF-β inactivation did not further accelerate tumorigenesis. This redundancy and the negative effect of TGF-β signaling on angiogenesis were also demonstrated using xenografts of human CRC cell lines. Furthermore, the analysis of the Cancer Genome Atlas data revealed that in CRC without microsatellite instability, overexpression of Myc and inactivation of Smads (including acquired mutations in SMAD2) are mutually exclusive, with odds ratio less than 0.1. CONCLUSIONS: In human CRC, gain-of-function alterations in Myc and loss-of-function alterations in TGF-β exhibit a masking epistatic interaction and are functionally redundant.
Authors: Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades Journal: Cell Date: 2011-09-01 Impact factor: 41.582
Authors: Prema Sundaram; Stacy Hultine; Lauren M Smith; Michael Dews; Jamie L Fox; Dauren Biyashev; Janell M Schelter; Qihong Huang; Michele A Cleary; Olga V Volpert; Andrei Thomas-Tikhonenko Journal: Cancer Res Date: 2011-10-25 Impact factor: 12.701
Authors: Adam J Bass; Michael S Lawrence; Lear E Brace; Alex H Ramos; Yotam Drier; Kristian Cibulskis; Carrie Sougnez; Douglas Voet; Gordon Saksena; Andrey Sivachenko; Rui Jing; Melissa Parkin; Trevor Pugh; Roel G Verhaak; Nicolas Stransky; Adam T Boutin; Jordi Barretina; David B Solit; Evi Vakiani; Wenlin Shao; Yuji Mishina; Markus Warmuth; Jose Jimenez; Derek Y Chiang; Sabina Signoretti; William G Kaelin; Nicole Spardy; William C Hahn; Yujin Hoshida; Shuji Ogino; Ronald A DePinho; Lynda Chin; Levi A Garraway; Charles S Fuchs; Jose Baselga; Josep Tabernero; Stacey Gabriel; Eric S Lander; Gad Getz; Matthew Meyerson Journal: Nat Genet Date: 2011-09-04 Impact factor: 38.330
Authors: Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides Journal: Nature Date: 2011-10-02 Impact factor: 49.962
Authors: Spiros A Vlahopoulos; Osman Cen; Nina Hengen; James Agan; Maria Moschovi; Elena Critselis; Maria Adamaki; Flora Bacopoulou; John A Copland; Istvan Boldogh; Michael Karin; George P Chrousos Journal: Cytokine Growth Factor Rev Date: 2015-06-20 Impact factor: 7.638
Authors: Priyanka Sehgal; Claudia Lanauze; Xin Wang; Katharina E Hayer; Manuel Torres-Diz; N Adrian Leu; Yogev Sela; Ben Z Stanger; Christopher J Lengner; Andrei Thomas-Tikhonenko Journal: Mol Cancer Res Date: 2021-09-30 Impact factor: 6.333
Authors: Claudia B Lanauze; Priyanka Sehgal; Katharina Hayer; Manuel Torres-Diz; James A Pippin; Struan F A Grant; Andrei Thomas-Tikhonenko Journal: Mol Cancer Res Date: 2021-02-19 Impact factor: 6.333
Authors: Giulia De Falco; Maria Raffaella Ambrosio; Fabio Fuligni; Anna Onnis; Cristiana Bellan; Bruno Jim Rocca; Mohsen Navari; Maryam Etebari; Lucia Mundo; Sara Gazaneo; Fabio Facchetti; Stefano A Pileri; Lorenzo Leoncini; Pier Paolo Piccaluga Journal: BMC Cancer Date: 2015-10-09 Impact factor: 4.430